Schreiner MediPharm’s High-Tech Digital Adherence Monitoring Solution Wins FINAT Award

Smart Blister Card enables real-time tracking of medication intake and patient adherence

Schreiner MediPharm, a Germany-based global provider of innovative functional label solutions for the healthcare industry, won a prestigious award for its Smart Blister Card from the European Association of the Self-Adhesive Label Industry (FINAT), which recognizes the industry’s best products. The Smart Blister Card, which extends standard multi-dose blister packs by a digital adherence monitoring tool enabling tracking of medication intake in real time, received the top honor in the “Innovation & Electronic Printing – Electronic Devices” category.

In the case of polypharmaceutical applications (permanent therapies involving the simultaneous prescription of several medications), pills are frequently filled into standard blister packs by hospital and large pharmacies so that patients can take them according to their medication plans. However, physicians and pharmacies typically have no way of tracking whether and when patients have taken their medicines. Schreiner MediPharm’s Smart Blister Card tackles this challenge by enabling digital medication adherence monitoring.

Integrated into the Smart Blister Card are conductive lines combined with an electronic unit. Once the patient pushes a tablet out of a cavity, data is generated in real time and includes information such as the exact time of pill removal, the respective cavity, and the dose it contains. The data is then stored in the Smart Blister Card and transmitted to a database via a smartphone app or a reader using NFC or Bluetooth technology.

For physicians and pharmacists, the handling of the Smart Blister Card is both convenient and flexible. After filling and sealing the blister pack, the Smart Blister Card is simply attached to the back of the pack without impairing the filling process. The technology can be inconspicuously integrated into the packaging design, and the marking of each cavity remains clearly visible. In addition, a temperature monitoring feature for sensitive ingredients is an available option.

The Smart Blister Card is suitable for nearly all existing multi-dose and single-dose blister packs. Patients can take their pills as usual because the cavities can be pushed through as easily as before. Additionally, smartphone apps can provide patients with digital self-monitoring support and even enable a reminder function to comply with their medication plan. Thus, Schreiner MediPharm’s Smart Blister Card helps enhance therapeutic success in polypharmaceutical applications.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”